BioNTech’s experimental cancer drug gotistobart nearly doubled median survival compared with chemotherapy in an updated lung-cancer trial analysis, strengthening one of the company’s late-stage oncology programs as it works to build a business beyond COVID-19 vaccines.
Patients with previously treated squamous non-small cell lung cancer who received gotistobart survived a median 18.5 months, compared with 10 months for patients receiving docetaxel chemotherapy. The updated analysis showed a 44% reduction in the risk of death, with a hazard ratio of 0.56 and a nominal p-value of 0.0295.
The results are encouraging, but they are not yet the data that could support approval.
They came from the non-pivotal first stage of BioNTech and OncoC4’s PRESERVE-003 Phase 3 trial. Only 87 patients with metastatic squamous NSCLC were included in the updated comparison: 45 received gotistobart and 42 received docetaxel.
The larger pivotal portion of the study is still underway, with overall survival as its primary endpoint. That upcoming result carries substantially more weight for BioNTech’s regulatory and commercial prospects.
BioNTech shares closed Monday at $98.86, up 2.2% from Friday, though the stock retreated from an intraday high above $102. The clinical update was presented during the World Conference on Lung Cancer in Seoul, alongside several other BioNTech oncology programs.
Updated Survival Data Remain Strong as Follow-Up Matures
The latest numbers extend an earlier survival signal BioNTech reported from PRESERVE-003.
In results published earlier this year after a median 14.5 months of follow-up, median survival had not yet been reached in the gotistobart group, while the docetaxel group had a median survival of 10 months. That analysis produced a hazard ratio of 0.46.
With follow-up now reaching a median 25.4 months, the hazard ratio has moved to 0.56. The magnitude of the benefit has therefore moderated as the data matured, but median survival with gotistobart still reached 18.5 months versus the same 10 months for chemotherapy.
Safety also remained broadly consistent with earlier findings.
Severe treatment-related adverse events of grade 3 or higher occurred in 44.4% of patients receiving gotistobart and 48.8% of those receiving docetaxel. That does not make the immunotherapy free of meaningful side effects, but it supports BioNTech’s argument that the survival benefit was achieved without an obvious increase in severe treatment-related toxicity compared with chemotherapy.
Gotistobart targets CTLA-4, an immune checkpoint involved in regulating T-cell activity. The antibody is designed to deplete regulatory T cells inside tumors while preserving more normal immune regulation elsewhere.
The investment case, however, does not depend on the mechanism being novel. It depends on whether the survival advantage holds up in the pivotal population.
The Pivotal Stage Is the Real Catalyst
PRESERVE-003 is designed as a two-stage Phase 3 study involving approximately 630 patients.
The first stage evaluated dosing and provided the survival results released Monday. The ongoing second stage compares the selected gotistobart dose directly with docetaxel in patients with squamous NSCLC whose cancer progressed after PD-1 or PD-L1 immunotherapy and platinum-based chemotherapy. The study is operating at more than 160 sites globally.
BioNTech said in August that it expected the first interim analysis from the pivotal stage during 2026 based on the pace at which survival events were occurring.
A positive pivotal result could open a regulatory path in a patient population with few treatment options. BioNTech has already received FDA Fast Track and Orphan Drug designations for gotistobart in lung cancer.
The commercial economics also matter.
BioNTech paid OncoC4 $200 million upfront in 2023 for exclusive worldwide rights to develop and commercialize gotistobart. The companies share development costs for the monotherapy and certain PD-1 combinations, while OncoC4 is eligible for milestone payments and double-digit tiered royalties if the drug reaches the market.
That leaves BioNTech with substantial commercial exposure if the program succeeds, but not the full economics.
Oncology Results Are Becoming More Important to BioNTech’s Valuation
The readout arrives as BioNTech spends heavily to turn itself from a COVID-vaccine-driven company into a broader oncology business.
Second-quarter revenue fell to €105.6 million from €260.8 million a year earlier as COVID vaccine demand weakened. BioNTech posted an €820.8 million quarterly net loss while spending €551 million on research and development, with gotistobart and its other immuno-oncology programs among the major drivers of R&D spending.
BioNTech can finance that development without immediate balance-sheet pressure. It ended June with €16.6 billion in cash, cash equivalents and security investments and now has 14 pivotal trials underway across its oncology pipeline.
That financial cushion gives the company time to wait for Phase 3 results, but investors still need evidence that years of cancer-drug investment can eventually produce approved products and meaningful revenue.
Gotistobart is now closer to answering that question.
The 18.5-month median survival result gives BioNTech a stronger clinical case than chemotherapy in the exploratory stage of PRESERVE-003, but the smaller non-pivotal dataset cannot establish the drug’s commercial future on its own.
The pivotal survival analysis is the next major test. If the larger study reproduces a clinically meaningful advantage without materially worsening safety, gotistobart could move from one of BioNTech’s promising oncology assets toward a credible approval candidate. If the survival gap narrows substantially as the trial expands, Monday’s strong result will matter far less than the headline suggests.